相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth
Yoshinobu Saitoh et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Fra-1 is upregulated in lung cancer tissues and inhibits the apoptosis of lung cancer cells by the P53 signaling pathway
Guangwei Zhong et al.
ONCOLOGY REPORTS (2016)
Panobinostat for the Treatment of Multiple Myeloma
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2015)
Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival
Sedef Iskit et al.
ONCOTARGET (2015)
p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
J. Sonnemann et al.
BRITISH JOURNAL OF CANCER (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Mechanisms of G1 cell cycle arrest and apoptosis in myeloma cells induced by hybrid-compound histone deacetylase inhibitor
Seiko Fujii et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Paul G. Richardson et al.
BLOOD (2013)
HDAC inhibitor DWP0016 activates p53 transcription and acetylation to inhibit cell growth in U251 glioblastoma cells
Hui Jin et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2013)
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
J. E. Bolden et al.
CELL DEATH & DISEASE (2013)
Role of the AP-1 transcription factor FOSL1 in endothelial cell adhesion and migration
Federico Galvagni et al.
CELL ADHESION & MIGRATION (2013)
The molecular role of Fra-1 and its prognostic significance in human esophageal squamous cell carcinoma
Akihiro Usui et al.
CANCER (2012)
Epigenetic cancer therapy: rationales, targets and drugs
M. Rius et al.
ONCOGENE (2012)
A decade of exploring the cancer epigenome - biological and translational implications
Stephen B. Baylin et al.
NATURE REVIEWS CANCER (2011)
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
Enrique M. Ocio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression
Y. P. Luo et al.
ONCOGENE (2010)
HDAC expression and clinical prognosis in human malignancies
Wilko Weichert
CANCER LETTERS (2009)
Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells
Tai-Lung Cha et al.
CLINICAL CANCER RESEARCH (2009)
Histone deacetylase inhibitors: Anticancer compounds
Karen T. Smith et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
W. Weichert et al.
BRITISH JOURNAL OF CANCER (2008)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma
Tatsuya Rikimaru et al.
ONCOLOGY (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
Patricia Maiso et al.
CANCER RESEARCH (2006)
The evolving classification of soft tissue tumours: an update based on the new WHO classification
CDM Fletcher
HISTOPATHOLOGY (2006)
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
ZH Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
A Insinga et al.
NATURE MEDICINE (2005)
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
P Zhu et al.
CANCER CELL (2004)
AP-1: A double-edged sword in tumorigenesis
R Eferl et al.
NATURE REVIEWS CANCER (2003)
Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells
T Hirota et al.
CELL (2003)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
AP-1 as a regulator of cell life and death
E Shaulian et al.
NATURE CELL BIOLOGY (2002)
Establishment and characterization of a cell line from a malignant fibrous histiocytoma of bone developing in a patient with multiple fibrous dysplasia
Z Fang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2002)
Establishment and characterization of cell line TNMY1 derived from human malignant fibrous histiocytoma
T Nakatani et al.
PATHOLOGY INTERNATIONAL (2001)
Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus
Y Kiyozuka et al.
CANCER GENETICS AND CYTOGENETICS (2001)
Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites
LL Huang et al.
ONCOGENE (2000)
分享论文
